Evidence for progressive cognitive decline in vascular dementia (VaD) is mixed, with some studies showing little or no decline over time. One possible explanation for these inconsistent findings is the heterogeneity of pathology encompassed by the VaD diagnosis. It is possible that subtypes of VaD (i.e. those resulting from different lesion distributions) show different patterns of cognitive decline. In the present study, a heterogeneous VaD group demonstrated cognitive decline from baseline to 12-month follow-up. Although this decline was coincident to morphometric changes (i.e. increased subcortical hyperintensities (SH), decreased whole brain volume (WBV)), no relationship emerged between cognitive decline and morphometric changes. Preliminary examination of VaD subtypes revealed patients with subcortical infarct or SH-only exhibited greater decline than VaD patients with cortical lesions. Further research is needed to determine whether this observed decline is attributable to differential lesion distribution or statistical artifact.
Vascular dementia (VaD) is believed to be the second most prevalent form of dementia (Leys et al., 1999) , accounting for 10-20% of all dementia cases (Geldmacher & Whitehouse, 1996) . However, cross-cultural rates vary widely (Liu et al., 1998; White et al., 1996) , and some researchers speculate VaD is more prevalent than Alzheimer's disease (AD) when including persons with stroke-related and cardiogenic VaD (Roman, 2002) .
Persons with VaD exhibit disproportionately impaired attention, executive functioning, and psychomotor speed performance, but relatively preserved memory function when compared to AD patients (Looi & Sachdev, 1999; Lukatela et al., 2000; Traykov et al., 2002) . However, it is unclear whether this pattern holds when patients are followed longitudinally. Some researchers posit that VaD patients exhibit a progressive deterioration in cognition, with decline associated with exacerbation of cerebrovascular pathology (Hachinski, Lassen, & Marshall, 1974) . This notion is supported by the decline exhibited in some longitudinal studies in global cognitive abilities (Ballard et al., 2001; Bowler et al., 1997; Meyer, Chowdhury, Xu, Li, & Quach, 2002) and domain specific tasks (Nyenhuis, Gorelick, Freels, & Garron, 2002; Paul et al., 2003) , particularly in the oldest VaD patients (Mungas, Reed, Ellis, & Jagust, 2001 ). However, support for progressive cognitive decline in VaD patients is far from universal, with many studies showing little or no decline over time (e.g. Moretti, Torre, Antonello, & Cazzato, 2001; Orgogozo, Rigaud, Stoffler, Mobius, & Forette, 2002; Pratt, 2002) .
Given these inconsistent findings, the present study had two primary goals. First, to document the natural history of persons with VaD on neuropsychological and neuroimaging measures over a 12-month period. Few studies have examined cognitive decline in VaD using a comprehensive battery of standardized neuropsychological measures or performed repeat magnetic resonance imaging (MRI) to identify structural changes that may account for decline.
A second goal of the present study was to provide a preliminary examination of differential decline across VaD subtypes. VaD is known to result from a number of mechanisms, including multiple infarction, strategic single infarction, microvascular disease, hypoperfusion, hemorrhage, or some combination thereof (Roman et al., 1993) . Given the differing physiological consequences of these mechanisms, it is possible that subtypes of VaD (i.e. those resulting from different lesion distributions) show different patterns or degree of cognitive decline (Nyenhuis & Gorelick, 1998 ).
Method

Participants
Data presented in the current paper are part of a larger study examining the efficacy of citicoline in the treatment of VaD . As part of the parent study, patients were randomized into either an active citicoline treatment condition or into a placebo control arm for the 12-month duration of the study. Results from the parent study indicated no effect of drug . Thus, all participants' data were pooled for the current analyses.
Data from twenty-five patients who participated in the parent study were included in the current study. All patients met both NINDS-AIREN (Roman et al., 1993) and DSM-IV (American Psychiatric Association, 1994) criteria for VaD, based on a comprehensive evaluation by a board-certified neurologist, which included clinical examination, medical history collected from each patient and at least one collateral informant, and review of structural neuroimaging scans. To participate in the current study, patients were required to be at least 55-years-old and have a Mini-Mental State Examination (MMSE; Folstein, Folstein, & McHugh, 1975 ) score between 9 and 24. An upper limit of 24 on the MMSE was selected to ensure patients were demented and a lower limit of 9 was selected to ensure participants had the cognitive capacity to participate in the study. Evidence of cortical infarction and/or periventricular or deep subcortical white matter lesions, in the absence of significant hippocampal atrophy, was required. Exclusion criteria included comorbid neurological disease, DSM-IV axis I disorder (other than dementia), systemic medical illness, and contraindications to MRI scan. No participant evidenced development of a new stroke or lacune over the followperiod.
Demographic and clinical data were collected at baseline. Patients were, on average, 77.9-years-old (S.D. = 5.4), 47% were women, 96% were Caucasian and they had an average of 12.3 (S.D. = 3.5) years of education. The mean baseline Hachinski score was 4.9 (S.D. = 3.7) and mean baseline MMSE score was 20.40 (3.84). On follow-up, MMSE scores averaged 19.07 (S.D. = 4.85), which was not significantly lower than baseline [F(1,24) = 1.75, P = .20]. All participants were able to complete tasks with their dominant hand and none were aphasic.
VaD subtype characteristics
To provide preliminary examination of differential decline across VaD subtypes, two patient subgroups were identified based on visual inspection of MRI findings by a board-certified neurologist. The first group (n = 9, age = 75.22 + 5.70) was comprised of patients with subcortical hyperintensities (SH) and evidence of cortical stroke. The second group (n = 16, age = 79.06 + 4.82), was defined as those patients with SH-only or SH and subcortical infarct (three basal ganglia, three thalamic infarct). Groups were similar in age, gender, educational attainment, and baseline MMSE scores, though the cortical stroke group had higher baseline Hachinski scores (t(23) = 2.60, P = .02). However, Hachinski score was unrelated to baseline measures of global cognitive performance (r = 0.13) and thus was not used as a covariate in subsequent analyses
Procedures
Magnetic resonance imaging and subcortical hyperintensity quantification
T1-(TR 500 ms, TE 20 ms), T2-(TR 2500 ms, TE 80 ms), and FLAIR-weighted (TR 6000 ms TE 105 ms) axial images were obtained using a Siemens Magnatom Vision 1.5 Tesla scanner. Slices were 5 mm with a 2 mm intersection gap. Subcortical hypertintensity (SH) quantification and whole brain volume (WBV) calculation techniques are described in greater detail elsewhere (Cohen et al., 2002) . Briefly, subcortical nuclei, periventricular regions, and white matter tracts, were examined on axial FLAIR images and included in analysis. A semiautomated thresholding technique allowed for the identification of SH based on the histogram distribution of pixel intensity. After a region of interest, which included white matter, grey matter, and cerebrospinal fluid, was identified, the number of pixels meeting criteria for SH was automatically quantified and summed in the 11 slices superior to the third ventricle. Research from our laboratory and by other investigators has demonstrated adequate validity and reliability with this technique (Jenkins et al., 1998; Greenwald et al., 1998) . To determine WBV, ventricular space was subtracted from total brain volume.
Neuropsychological assessment
Patients received a comprehensive neuropsychological examination and structural MRI at baseline and at 12-month follow-up. All tests were administered according to standard procedures by trained research team members. Baseline evaluations were conducted prior to enrollment in the citicoline treatment study. The neuropsychological battery used was designed to assess cognitive functioning in several domains, including attention/psychomotor functioning [trailmaking test part A (Reitan, 1958) , digit symbol coding (Wechsler adult intelligence test-revised; (WAIS-R; Wechsler, 1981) ), digit span (WAIS-R; Wechsler, 1981) , grooved pegboard test for dominant hand (Klove, 1963) ], executive functioning [controlled oral word association test (COWAT; Eslinger, Damasio, & Benton, 1984) , similarities test (WAIS-R; Wechsler, 1981) , stroop color word test (Golden, 1978) ], memory [complex figure test (CFT; Rey, 1941) delayed free recall and recognition trials, California verbal learning test-I (CVLT; Delis et al., 1987) ], language [Boston naming test (BNT; Kaplan, Goodglass, & Weintraub, 1983) , category fluency (Morris et al., 1989) , vocabulary test (WAIS-R; Wechsler, 1981) ], and spatial skills [Hooper visual organization test (HVOT; Hooper, 1983) , block design (WAIS-R; Wechsler, 1981) , complex figure test-copy (CFT; Rey, 1941) ]. Baseline and follow-up individual test scores for each domain is listed in Table 1 .
Data analysis
Repeated measures MANOVA was used to determine possible morphometric and cognitive changes from baseline to 12-month follow-up. Post-tests were used to clarify significant omnibus findings. Degree of clinical decline was determined by comparing participant performance to established normative data (Trails A, Stroop, COWAT, BNT: Ivnik, Malee, Smith, & Petersen, 1996; animals: Tombaugh et al., 1999; CVLT: Paolo, Troster, & Ryan, 1997; CFT: Meyers & Meyers, 1995; Pegs: Harley, Leuthold, Matthews, & Bergs, 1980) . Change scores in cognitive tests showing significant decline were then correlated to changes in SH and WBV to identify possible contribution to decline. Pairwise deletion was employed in all analyses as appropriate.
Results
Entire sample
Morphometric changes in entire sample
Repeated measures MANOVA indicated significant morphometric changes from baseline to follow-up, Λ = .50 [F(2, 24) = 11.89], P < .001. Post-tests revealed both a significant increase 
Cognitive changes in entire sample
VaD patients showed a decline in language performance, Λ = .63 [F(3, 27) = 5.28], P = .005. Post-tests revealed significant decline in Boston naming test and vocabulary from baseline to follow-up. No change from baseline to follow-up was found in attention/psychomotor speed, executive, memory, or spatial domains, see Table 1 .
Given the small sample size used for these multivariate tests, exploratory analyses were conducted to identify other cognitive tasks with decline from baseline to follow-up. Repeated measures ANOVA showed VaD patients declined on complex figure test recognition [F(1, 28) = 5.60, P = .03] and Hooper visual organization test [F(1,28) = 4.60, P = .04]. Due to the increased possibility of a type I error, these significant findings should be interpreted cautiously. The degree of clinical decline of VaD patients from baseline to follow-up appears in Table 2 . Raw test performance was transformed to standard scores (WAIS-R subtests) or t-scores (all others) to demonstrate degree of clinical decline. Performance was corrected for age, sex, and education whenever possible. Results suggest continued cognitive decline in VaD patients, above and beyond poor baseline performance.
Relationship between morphometric and cognitive changes in entire sample
No significant relationships emerged between morphometric and cognitive changes, see Table 3 . 
Decline in VaD patients with cortical lesion
In terms of morphometric changes, VaD patients with cortical lesion exhibited significant decrease in WBV from baseline to follow-up [F(1,8) = 8.18, P = .02] and a trend toward increased SH [F(1,8) = 4.08, P = .08]. See Table 4 . In terms of cognition, no change from baseline to follow-up was found in attention/psychomotor speed, executive, language, or spatial domains. Significant changes were found in the memory domain [Λ = .14 [F(4, 5) = 7.49], P = .02] with patients showing improved CVLT Discrimination at follow-up.
Decline in VaD patients with subcortical lesion or SH-only
On MRI, VaD patients with subcortical infarct or SH-only showed both WBV atrophy [F(1,15) = 5.72, P = .03] and increased SH [F(1,15) = 11.81, P < .01] from baseline to follow up. See Table 5 . In terms of cognition, no change from baseline to follow up was found for memory or spatial domains. However, decline was noted in attention/psychomotor speed tasks [Λ = .39 [F(4,12 
Comparison of cortical versus subcortical subtypes
Finally, we directly examined changes from baseline to follow-up across VaD subtypes. MANOVA indicated no difference in brain changes or executive, memory, language, and spatial domains. However, VaD patients with subcortical infarct/SH-only showed greater decline on attention/psychomotor speed tasks, [Λ = .52 [F(4,19) = 4.31], P = .01], with greater decline on trail making test A and pegboard dominant hand performance from baseline to 12-month follow-up.
Discussion
The present study found persons with VaD demonstrated cognitive decline from baseline to 12-month follow-up. Although this decline was coincident to morphometric changes (i.e. increased SH, decreased WBV), no relationship emerged between cognitive decline and morphometric changes. Preliminary analyses suggest the possibility that different VaD subtypes may show differential decline, though replication in larger samples is needed.
Within these findings are four important areas of discussion. First, past studies of persons with VaD are inconsistent in their support for progressive cognitive decline. In the present study, VaD patients as a group showed significant decline from baseline to 12-month followup in tasks tapping confrontation naming and expressive vocabulary skills. No such decline emerged on tasks tapping attention, executive function, memory, or spatial tasks. Although a language-based decline runs counter to the deficits typically expected of VaD, past studies have reported similar findings (e.g. Nyenhuis et al., 2002) . Much like the findings of Nyenhuis et al. (2002) , it is unclear whether this pattern of decline reflects the natural progression of VaD or statistical artifact. Although the measures selected for this study are commonly used in clinical evaluations, persons with VaD often perform very poorly on testing, with their performance below the most sensitive range of the test. In addition, many persons with VaD are often diagnosed by their poor performance on tasks tapping attention, executive function, and psychomotor speed, and participants may "bottom out" during baseline assessment and have no opportunity for measurable decline at follow-up. This possibility is a potential limitation of the current and other studies assessing cognitive decline in persons with dementia.
Closely related to this finding is that morphometric changes were unrelated to cognitive decline. Although our VaD sample showed significant increases in SH and decreases in WBV from baseline to follow-up, these changes were unrelated to decline in cognitive performance. The findings between cognition and MRI abnormalities are inconsistent for community dwelling elderly, with some finding increased dementia risk (e.g. Vermeer et al., 2003) and others finding no relationship (Piguet et al., 2003) . In persons with known cardiovascular disorders, MRI measures of atrophy, white matter changes, and number of infarcts are associated with an increased dementia risk (Kuller et al., 2003) . Given such findings, it is possible that a threshold exists for the cognitive consequences of cerebrovascular-related morphometric changes. Early changes in SH or WBV may result in cognitive deterioration, but after reaching sufficient severity, additional brain changes no longer correspond to cognitive decline. However, contrary to this notion, studies of persons with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) show cognitive decline at higher levels of lesion load than found in the VaD patients of the present study (e.g. Filley et al., 1999) .
Our comparison of VaD patients' performance to normative data also provided some interesting findings. As expected, performances were frequently poor and often fell in the severely impaired range. However, a surprisingly large percentage of participants generated intact performances on most tests, including 52% on digit span, 42% on trail making test A, 44% on vocabulary, and 36% on Hooper visual organizational test. Comparison to normative data also reveals persons with VaD do not exhibit universal decline in performance over time, with the percent of intact performances generally remaining consistent (or actually showing small gains) on most tests. Such findings are an important reminder of the heterogeneous presentation of VaD and of the intra-individual variability in repeated test performance.
Finally, the present study offered preliminary evidence that VaD subtypes may show differential decline over time. This finding is consistent with the hypotheses of other researchers (e.g. Nyenhuis & Gorelick, 1998) . In the present study, VaD patients with subcortical infarct or SH-only showed greater cognitive decline than those with cortical infarct and exhibited decline on tasks tapping attention/psychomotor speed, executive functioning, and language abilities. Complicating interpretation of these findings is the baseline differences between cortical and subcortical VaD patients. As discussed in above sections, it remains unclear whether the differential decline reflects true differences across subtypes or statistical artifact from patients "bottoming out" on testing. Additional research in this area is needed.
The degree to which manifestation of these VaD subtypes predispose individuals to neurodegenerative pathology is an important area of further study. Neuropathological studies show VaD without evidence of neurodegenerative processes is relatively rare (e.g. Bowler, Munoz, Merskey, & Hachinski, 1998; Nolan, Lino, Seligmann, & Blass, 1998) , suggesting that VaD is in fact a very uncommon disorder or that many VaD patients convert to mixed dementia if surviving for sufficient time. Cerebrovascular disease may limit the brain's ability to eliminate beta amyloid deposits (Weller & Nocoll, 2003) and presence of both vascular and neurodegenerative lesions is known to adversely affect cognition more than either risk factor independently (e.g. Snowdon et al., 1997; Zekry et al., 2002) . Given these findings, future studies of the progression of cognitive deficits in VaD should include pathological examination to clarify possible conversion to MD.
The findings of the present study may not generalize to all other samples. The sample employed in final analyses was relatively small, thus limiting observed power in multivariate analyses. It is possible that additional evidence for progressive cognitive decline would have emerged in larger samples. Another possible limitation is the inclusion of VaD patients with both subcortical infarct and SH-only in the same comparison group. It is possible that these groups also show differential cognitive decline relative to each other and the cortical lesion group, though our relatively small sample precludes conducting such analyses. A large-scale longitudinal study is needed to more clearly determine the rate and pattern of decline in various VaD subtypes. Finding VaD subtypes decline at different rates has important clinical implications. Recent years have seen increased use of pharmacological treatment to alleviate cognitive symptoms or prevent further cognitive decline in persons with VaD (e.g. Moretti et al., 2001; Pratt, 2002) . Given the different etiologies and pattern of cognitive decline, different subtypes of VaD may show differential response to treatment. Further evaluation of this possibility may reduce the financial and psychosocial burden of VaD.
